Physician profile
Siqing Li
NPI 1942243910
$4,369.07
in general payments reported to CMS, 2019-2025
13 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $666 · 2021: $509 · 2022: $939 · 2023: $355 · 2024: $468 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.88 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,908.89 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $817.10 | 2019-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $340.21 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $273.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $252.70 | 2019-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $239.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $216.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $134.62 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.97 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $33.79 | 2019-2021 | |
| Ethicon US, LLC | $28.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.57 | 2022 | |
| Abbvie INC. | $20.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siqing Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.